An update review of intradialytic hypotension: concept, risk factors, clinical implications and management

Mehmet Kanbay, Lale A. Ertuglu, Baris Afsar, Elif Ozdogan, Dimitrie Siriopol, Adrian Covic, Carlo Basile and Alberto Ortiz

Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey, Department of Internal Medicine, Division of Nephrology, Suleyman Demirel University School of Medicine, Isparta, Turkey, Nephrology Clinic, Dialysis and Renal Transplant Center, C.I. PARHON University Hospital, 'Grigore T. Popa' University of Medicine, Iasi, Romania, Division of Nephrology, Miulli General Hospital, Acquaviva delle Fonti, Italy, Associazione Nefrologica Gabriella Sebastio, Martina Franca, Italy and Dialysis Unit, School of Medicine, IIS-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain

Correspondence to: Mehmet Kanbay; E-mail: drkanbay@yahoo.com; mkanbay@ku.edu.tr; Twitter handle: @CKJ_EiC

ABSTRACT

Intradialytic hypotension (IDH) is a frequent and serious complication of chronic haemodialysis, linked to adverse long-term outcomes including increased cardiovascular and all-cause mortality. IDH is the end result of the interaction between ultrafiltration rate (UFR), cardiac output and arteriolar tone. Thus excessive ultrafiltration may decrease the cardiac output, especially when compensatory mechanisms (heart rate, myocardial contractility, vascular tone and splanchnic flow shifts) fail to be optimally recruited. The repeated disruption of end-organ perfusion in IDH may lead to various adverse clinical outcomes affecting the heart, central nervous system, kidney and gastrointestinal system. Potential interventions to decrease the incidence or severity of IDH include optimization of the dialysis prescription (cool dialysate, UFR, sodium profiling and high-flux haemofiltration), interventions during the dialysis session (midodrine, mannitol, food intake, intradialytic exercise and intermittent pneumatic compression of the lower limbs) and interventions in the interdialysis period (lower interdialytic weight gain and blood pressure–lowering drugs). However, the evidence base for many of these interventions is thin and optimal prevention and management of IDH awaits further clinical investigation. Developing a consensus definition of IDH will facilitate clinical research. We review the most recent findings on risk factors, pathophysiology and management of IDH and, based on this, we call for a new consensus definition of IDH based on clinical outcomes and define a roadmap for IDH research.

Keywords: cardiovascular event, haemodialysis, intradialytic hypotension, roadmap, ultrafiltration
INTRODUCTION

Despite recent advances in dialysis techniques, the high mortality of end-stage renal disease (ESRD) patients remains a major challenge, with the majority depending on haemodialysis (HD) to replace renal function [1]. Intradialytic hypotension (IDH) is one of the most common complications of HD in clinical practice due to the older average age of dialysis patients and the increasing prevalence of comorbidities such as diabetes mellitus and heart failure (HF). The prevalence of IDH ranges from 8 to 40% in different studies [2–5]. The reasons for the discrepancy in IDH prevalence in these studies are not completely known but might be due to using different definitions of IDH and/or to different patient characteristics [age, prevalence of diabetes or cardiovascular disease, interdialytic weight gain (IDWG), body weight and gender distribution]. While IDH causes significant patient distress during dialysis sessions, it is also strongly associated with vascular access failure, cardiovascular events, end-organ damage, and mortality, emphasizing the need to optimize preventive and therapeutic strategies.

This review discusses the most recent findings on risk factors, pathophysiology and management of IDH. Based on this, we call for a new consensus definition of IDH, suggest a methodology for its development and propose a roadmap for IDH research.

IDH DEFINITION

Increasing our understanding of IDH is restricted by the absence of a consensus medical definition (Table 1). Definitions differ in the blood pressure (BP) parameter used (decrease in systolic BP (SBP), nadir SBP, decrease in mean arterial pressure (MAP)), the cut-off value for the BP parameter and the need for symptoms and/or intervention. The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative guidelines in 2005 defined IDH as a decrease in either SBP >20 mmHg or MAP >10 mmHg leading to symptoms [6]. Other definitions given in different guidelines are (i) any episode of a decrease in BP during dialysis that requires an immediate intervention, like ultrafiltration reduction or saline infusion, (ii) a symptomatic decrease in either SBP >20 mmHg or MAP >10 mmHg that needs intervention and (iii) a symptomatic sudden drop in SBP >30 mmHg or a decrease in MAP >10 mmHg [14]. Similarly, the European Best Practice Guidelines (EBPGs) defined IDH as a decrease in SBP >20 mmHg in combination with clinical events and interventions [10]. An ideal definition should incorporate the concept of ‘consequences for health’, as does the chronic kidney disease (CKD) definition [15]. It may be argued that the development of symptoms and/or the need for intervention is already a consequence for health that may negatively impact quality of life. However, many databases do not accurately collect symptoms and nursing interventions that may additionally have a subjective component. Thus, many studies prefer using a decrease in systolic BP by a specific amount (20, 30 and 40 mmHg) or nadir systolic BP below a threshold (90, 95 and 100 mmHg) [16]. When using only specific BP cut-off values, defining ‘consequences for health’ is even more necessary. In a recent study, Flythe et al. [16] evaluated the differences between various IDH definitions in the Hemodialysis (HEMO) and Large Dialysis Organization (LDO) study cohorts. In patients with pre-dialysis SBP <160 mmHg, nadir SBP <90 mmHg had the strongest association with mortality, while this value changed to nadir SBP <100 mmHg in patients with pre-dialysis SBP ≥160 mmHg. IDH definitions that contained symptoms, interventions or decreases in BP during the dialysis session were not associated with mortality [16]. However, caution should be exercised to possible confounders in observational studies, and randomized controlled trials are needed before a definitive definition of IDH can be established. Due to the lack of such evidence and consensus, the discrepancies in IDH definitions have hindered data collection for accurate estimation of IDH prevalence, risk factors and consequences, as well as for evidence-based strategies for IDH prophylaxis and treatment and the impact of such strategies on adverse clinical outcomes (Table 2).

PATHOPHYSIOLOGY OF IDH

IDH is the end result of the interaction between ultrafiltration rate (UFR), cardiac output and arteriolar tone. Thus excessive ultrafiltration may decrease cardiac output, especially when compensatory mechanisms (heart rate, myocardial contractility, vascular tone and splanchic flow shifts) fail to be optimally recruited.

Ultrafiltration and total volume removal

Fluid extraction by ultrafiltration results in a sudden fluid compartment change that causes BP instability. The UFR is a key predisposing factor to IDH, especially when it exceeds the plasma refill rate, with the risk for IDH increasing greatly with...
products during HD may lead to the formation of transient os- 

currence of IDH [21]. On top of the UFR, rapid clearance of waste 

clearance of HD treatment 

of IDH. During HD, cardiac output depends on preload, after-

load, heart rate and contractility. Changes in preload and after-

load, determined mainly by intravascular volume and arteriolar 

vascular resistance, respectively, seem to play a major role in 

the development of IDH, while heart rate and contractility have 

a minor compensatory role [21]. However, the loss of compensa-

tion from increased contractility predisposes to the develop-

ment of IDH in patients with CHF. Given that approximately 
one-third of HD patients have CHF at the time of initiation of di-

alysis therapy, a decrease in contractility is a prevalent risk fac-

tor for the development of IDH [22]. In a small study of 10 

patients with no history of CHF or ischaemic heart disease, 

patients prone to IDH were found to have impaired myocardial 

contractility reserve assessed by response to dobutamine atro-

pine stress [23]. While decreased myocardial function predis-

tosposes to the development of IDH, it is also shown that IDH itself 

causes myocardial stunning, a phenomenon known as reversible 

myocardial contractility due to ischaemia [23].

**Arteriolar tone**

A failure to maintain arteriolar tone during HD has been pro-

posed to be a cause of IDH for >2 decades [24–26]. In normal 

physiology, a reduction in intravascular volume would lead to 
increased sympathetnic outflow, thus to arteriolar vasoconstrict-

tion and increased peripheral vascular resistance, helping to 
maintain BP. Sympathetic discharge and baroreceptor sensitiv-

ity were hypothesized to be diminished in some HD patients 
[25, 27, 28]. In several studies, heart rate variability (HRV), a non-

invasive method to estimate autonomic dysfunction, was used to 

assess sympathetic activity during HD. While HRV is in-

creased during HD, signifying sympathetic activation, such a 
sympathetic response, was not seen in patients prone to IDH 
[29, 30]. Blunted sympathetic activation may hinder compen-

satory mechanisms and increase IDH incidence and severity. 
The prevalence of cardiovascular autonomic dysfunction in chronic 

HD patients was suggested to be as high as 50% [31].

In healthy individuals, plasma osmolarity is tightly regu-

lated by thirst and arginine vasopressin (AVP) [32]. Since ESRD 

patients on HD have little to no renal response to AVP, baseline 

AVP levels in dialysis patients are higher than in healthy con-

trols; however, they fail to increase in response to HD [33, 34]. 
The loss of vasoconstrictive effect of AVP via activation of 

V1 receptors in vascular smooth muscle cells in HD patients 

may contribute to IDH, and this offers the opportunity for thera-

cutic intervention, as discussed below [35–37].

Suboptimal splanchnic blood flow shifts may also contribute 

to IDH. Monitoring of splanchnic blood flows during HD using 
radiolabelled erythrocytes disclosed that within 30 min of ultra-

filtration, a rapid central shift of the splanchnic blood pool was 

observed, possibly contributing to maintain BP values in the 
early phase of HD. A loss of such a shift in patients with auto-

nomic dysfunction [38], as well as food ingestion, which causes 
a similar splanchnic sequestration [39], were suggested to pre-

dispose to IDH.

In the past, acetate was used as a dialysis solution base. 

Acetate has well-known vasodilator properties and therefore 

was an important cause of IDH historically [21]. Today, the use 
of bicarbonate-based dialysates has eliminated such predisposi-

tion around the world.

**Risk factors**

Risk factors for the development of IDH include diabetes mellitus; 

cardiovascular disease including systolic and diastolic dys-

function, ischaemic heart disease, arrhythmias and vascular 
calcification; autonomic dysfunction; poor nutritional status;

| Prevention of IDH                                                                 |
|----------------------------------------------------------------------------------|
| 1. Evaluate patients for hydration status (prior to the session), frequently for  |
| BP and heart frequency rate (during the session) and, if frequent IDH episodes,  |
| for cardiovascular disease                                                          |
| 2. Lifestyle interventions:                                                         |
| a. Decrease salt intake                                                             |
| b. Avoid food intake during or just before dialysis if frequent episodes of IDH   |
| c. Avoid routine sodium profiling with supraphysiological dialyserate sodium       |
| concentrations                                                                     |
| d. The use of a dialyserate calcium concentration of 1.50 mmol/L should be        |
| considered and low-magnesium (0.25 mmol/L) dialyserate should be avoided,        |
| especially in combination with low-calcium dialyserate in patients with frequent  |
| episodes of IDH                                                                     |
| e. Cool dialyserate temperature dialysis (35–36 °C) or isothermic treatments      |
| by blood temperature-controlled feedback should be prescribed in patients with    |
| frequent episodes of IDH                                                             |
| f. Haemo(dia)filtration techniques should not be considered a first-line option  |
| for the prevention of IDH, but as a possible alternative to cool dialysis          |
| g. A prolongation in dialysis time or an increase in dialysis frequency           |
| should be considered in patients with frequent episodes of IDH                     |
| 4. In patients with frequent episodes of IDH, antihypertensive agents should be   |
| given with caution prior to dialysis depending on pharmacodynamics, but should    |
| not be routinely withheld on the day of HD treatment                               |
| 5. If other treatment options have failed, then consider switching to PD or mido-  |
| drine or L-carnitine supplementation                                                |
| **Treatment of IDH**                                                               |
| 1. Trendelenburg position should be considered                                       |
| 2. Ultrafiltration should be stopped during an episode of IDH                        |
| 3. Isotonic saline should be infused in patients unresponsive to stopping ultra-   |
| filtration and Trendelenburg position during an episode of IDH                      |
| 4. Infusion of colloid solutions should be considered in patients who remain       |
| unresponsive to saline infusion                                                     |

**Table 2. EBPGs on haemodynamic instability 2007 [8]: key messages**

| Prevention of IDH                                                                 |
|----------------------------------------------------------------------------------|
| 1. Evaluate patients for hydration status (prior to the session), frequently for  |
| BP and heart frequency rate (during the session) and, if frequent IDH episodes,  |
| for cardiovascular disease                                                          |
| 2. Lifestyle interventions:                                                         |
| a. Decrease salt intake                                                             |
| b. Avoid food intake during or just before dialysis if frequent episodes of IDH   |
| c. Avoid routine sodium profiling with supraphysiological dialyserate sodium       |
| concentrations                                                                     |
| d. The use of a dialyserate calcium concentration of 1.50 mmol/L should be        |
| considered and low-magnesium (0.25 mmol/L) dialyserate should be avoided,        |
| especially in combination with low-calcium dialyserate in patients with frequent  |
| episodes of IDH                                                                     |
| e. Cool dialyserate temperature dialysis (35–36 °C) or isothermic treatments      |
| by blood temperature-controlled feedback should be prescribed in patients with    |
| frequent episodes of IDH                                                             |
| f. Haemo(dia)filtration techniques should not be considered a first-line option  |
| for the prevention of IDH, but as a possible alternative to cool dialysis          |
| g. A prolongation in dialysis time or an increase in dialysis frequency           |
| should be considered in patients with frequent episodes of IDH                     |
| 4. In patients with frequent episodes of IDH, antihypertensive agents should be   |
| given with caution prior to dialysis depending on pharmacodynamics, but should    |
| not be routinely withheld on the day of HD treatment                               |
| 5. If other treatment options have failed, then consider switching to PD or mido-  |
| drine or L-carnitine supplementation                                                |
| **Treatment of IDH**                                                               |
| 1. Trendelenburg position should be considered                                       |
| 2. Ultrafiltration should be stopped during an episode of IDH                        |
| 3. Isotonic saline should be infused in patients unresponsive to stopping ultra-   |
| filtration and Trendelenburg position during an episode of IDH                      |
| 4. Infusion of colloid solutions should be considered in patients who remain       |
| unresponsive to saline infusion                                                     |
hypoalbuminaemia; female sex; age >65 years; pre-dialysis SBP <100 mmHg; high body mass index and severe anaemia [3, 28, 40].

High IDWG may also be a predisposing factor as it may require higher UFR [7]. In a retrospective study of 255 patients, absolute IDGW, but not percent IDGW, was a risk factor for IDH [41], while in a retrospective study of 39,497 patients, both absolute and relative IDGW were significant risk factors [7]. It was also suggested that the first HD session of the week was associated with a higher IDH risk in thrice-weekly HD [4]. In a cohort study of 293 patients with a 40% incidence of IDH, UFR, N-terminal pro-B type natriuretic peptide and β2 microglobulin were also found to be independently associated with IDH [2]. An ongoing cohort study that was expected to be completed by July 2019 recruited 90 participants to examine the correlation between diabetes status and IDH (ClinicalTrials.gov identifier NCT03870594). Further prevalence and risk factor studies are needed once a consensus definition of IDH is available that eliminates the current inconsistencies in the IDH definitions.

CONSEQUENCES OF IDH

IDH is associated with several significant clinical outcomes. The best established association of IDH is with cardiovascular events and mortality. In a retrospective study of 39,497 HD patient records, IDH was associated with myocardial infarction, hospitalization for HF/volume overload and cardiovascular and all-cause mortality [7]. Indeed, several studies have confirmed that IDH is an independent risk factor for all-cause mortality [2, 7, 12, 16, 42]. For instance, in a US-based cohort of 112,013 incident HD patients, a direct linear relationship between IDH and mortality was demonstrated, with a mortality hazards ratio (HR) of 1.49 [95% confidence interval (CI) 1.42–1.57] among patients who had IDH in >40% of their HD sessions [12]. However, there have also been reports to the contrary [43]. Such disagreeing results may be due to the different definitions of IDH used in many of those studies, including nadir intradialytic SBP <90 mmHg [12] and an SBP <90 mmHg associated with symptoms of hypotension and necessitating fluid administration [43].

IDH is independently associated with myocardial stunning, which in turn is associated with cardiovascular events and mortality [23, 44]. The reversible myocardial stunning due to repetitive reversible ischaemia within each IDH episode may initiate a pathway from myocardial hibernation to eventual irreversible myocardial fibrosis and irreversible systolic dysfunction [45]. The development of HF in HD patients predicts a significantly poorer outcome, and cardiovascular mortality is 30-fold more frequent in HD patients than in age-matched controls [46]. The management of IDH in patients with decreased left ventricular function can be challenging, as the acute management of IDH primarily consists of stopping ultrafiltration and administration of fluids [28], which may exacerbate an underlying HF. In such patients who are prone to myocardial stunning or already have myocardial dysfunction, IDH prevention is essential. Indeed, a randomized crossover study with 10 patients showed that dialysis-induced left ventricular regional wall motion abnormalities were improved by cooling the dialysate [46], a simple and effective method to decrease IDH incidence that is discussed below. Another randomized crossover study reported a similar significant decrease in left ventricular regional wall motion abnormalities along with significantly fewer IDH episodes in biofeedback dialysis, which modulated UFRs and dialysate sodium concentration in response to relative blood volume [47].

Another concern for HD patients with cardiac comorbidities is the dialysate calcium concentration. A recent retrospective cohort study observed that lower facility levels of dialysate calcium (≤2.5 mEq/L) were associated with more frequent hospitalizations for HF exacerbation and also with more frequent IDH episodes [48]. Indeed, in prior reports, higher dialysate calcium concentrations were associated with an increase in left ventricular contractility in patients with normal cardiac function [49], as well as in patients with HF (New York Heart Association classifications III and IV) [50]. Intradialytic systolic and diastolic BPs were higher in patients receiving the dialysate with a higher calcium concentration (1.75 versus 1.25 mmol/L) [50]. However, the long-term effects of various IDH management strategies are subject to longitudinal clinical trials.

Another manifestation of end-organ damage caused by IDH is cerebral ischaemia. When BP and cerebral oxygenation were recorded during 635 HD sessions in 58 patients, every 10 mmHg decrease from baseline MAP was associated with a 3% increase in ischaemic events (P < 0.001), although no clear ‘safe’ MAP threshold could be determined, due to the presence of different cerebral autoregulation limits for each patient [51]. The potential clinical consequence of such repeated cerebral ischaemia was explored by Mizumasa et al. [52]. They assessed frontal atrophy indexes with magnetic resonance imaging in 32 HD patients twice after a 3-year interval and counted all IDH episodes during the same interval. The change in frontal atrophy indexes inversely correlated with the number of IDH episodes (r = 0.45, P < 0.05) [52]. In a 1-year long randomized clinical trial, patients treated with cooler dialysate (0.5°C below core body temperature) had fewer IDH episodes than patients on 37°C dialysate and showed no brain white matter changes after 1 year, while patients on 37°C dialysate exhibited the pattern of ischaemic brain injury (increased fractional anisotropy and reduced radial diffusivity) seen in HD patients [53]. Moreover, new evidence suggests that IDH-induced damage may cause dementia in the long term in older populations. In a cohort of 31,055 elderly HD patients, the cumulative exposure to frequent IDH was significantly associated with a 5-year risk of new-onset dementia. Patients who experienced seven or more episodes of IDH in 90 days had the highest 5-year risk of new-onset dementia [HR 1.36 (95% CI 1.20–1.48)] [54]. This possible association between cerebral ischaemia and IDH may explain the observation that cognitive impairment is more frequent in chronic HD than in peritoneal dialysis (PD) patients [55].

Mesenteric ischaemia and even liver ischaemia are rare forms of end-organ damage associated with IDH [56]. A case-control study including 626 patient with a hospitalized mesenteric ischaemia event and 2428 controls observed a direct association of the proportion of IDH (defined as nadir intradialytic SBP <90 mmHg) with hospitalized mesenteric ischaemia (P for trend = 0.001) [57]. Several previous case series studies of HD patients also described hypotensive episodes preceding mesenteric ischaemia events [58, 59]. Similarly, case reports have observed other rare complications of chronic HD occurring immediately after IDH episodes. For example, a patient developed non-arteritic anterior ischaemic optic neuropathy three times in 4 months; each episode was noticed at the end of a dialysis session complicated by IDH [60].

IDH accelerates the loss of residual renal function (RRF). RRF preservation has strong survival benefits in both PD patients [61] and HD patients [62]. RRF has a significant role in fluid balance, toxin clearance and calcium-phosphorus metabolism and its decline is associated with more severe anaemia, inflammation and malnutrition as well as cardiovascular morbidity and
mortality [17]. Because RRF is lost more rapidly in patients on HD than in patients on PD [61], IDH is a suspected driver of this crucial difference. In a prospective study with 279 incident dialysis patients, IDH was independently associated with a faster renal function decline rate in the first 3 months of HD [63]. Given that the decline in RRF is greater during the first 3 months [64], IDH should be avoided in new dialysis patients with higher RRF. As these patients have residual diuresis, a key factor is to avoid excessive ultrafiltration.

IDH was also associated with vascular access thrombosis, a very troublesome complication for chronic HD patients [65]. In the HEMO study cohort of 1426 HD patients, the highest quartile of IDH had an ~2-fold higher independent relative rate of native arteriovenous fistula thrombosis than the lowest quartile during a median of 3.1 years. However, IDH was not associated with prosthetic arteriovenous graft thrombosis [65].

Besides the detrimental long-term consequences, IDH is a major cause of distress in patients during the HD sessions, as it may cause lightheadedness, weakness, headache, nausea and vomiting [66]. Although definitions of IDH based solely on the magnitude of decrease in SBP do not sufficiently capture patient symptoms, these are a major determinant of quality of life in dialysis patients [67]. In addition, such symptoms may cause the HD session to be terminated earlier, resulting in inadequate toxin and fluid elimination.

**PREVENTION AND TREATMENT**

Several approaches have been suggested to decrease the incidence or severity of IDH. These include optimization of the dialysis prescription (cool dialysate, UFR, sodium profiling, high-flux haemofiltration), interventions during the dialysis session (midodrine, fluid administration, food intake, intradialytic exercise and intermittent pneumatic compression of the lower limbs), interventions in the interdialysis period (lower IDWG and BP-lowering drugs) and switching the modality to PD (Figure 1).

**Cool dialysate**

Reducing the temperature of the dialysate below the core body temperature is one of the most-used preventive methods against IDH. In fact, EBPGs recommend the use of cool dialysate as a first-line option to prevent IDH [10] (Table 2). Cool dialysate decreases the risk of IDH development by inducing vasoconstriction and activating the sympathetic nervous system [68]. In a meta-analysis of 26 trials including a total of 484 patients, cool dialysis reduced the rate of IDH by 70% (95% CI 49–89) and increased intradialytic BP by 12 mmHg (95% CI 8–16), while the adequacy of dialysis was not affected, with no significant difference in $K_t/V_{urea}$ [69]. Similarly, a systematic review of 22 studies including 408 patients determined that IDH occurred 7.1-fold (95% CI 5.3–8.9) less frequently and post-dialysis MAP was 11.3 mmHg (95% CI 7.7–15.0) higher with cool dialysis. Moreover, none of the studies showed a reduction in urea clearance, a measure of dialysis adequacy, with cool dialysate [70]. In clinical trials, cool dialysate was also reported to prevent IDH-related complications such as myocardial stunning [46], HD-associated cardiomyopathy [71] and HD-related brain white matter changes [53]. While the efficacy of cool dialysate is proven in chronic HD patients, its efficacy in preventing IDH in acute kidney injury (AKI) patients receiving sustained low-efficiency dialysis will be assessed in an ongoing randomized trial with 38 patients (ClinicalTrials.gov identifier NCT03397992), following previous promising results [72]. Using cool dialysate is completely safe, simple and entails no additional costs. The one drawback is the unpleasant sensations described by many patients, which reduce patient tolerability [69]. Nevertheless, an anecdotal small study of 10 HD patients reported that 8/10 patients who experienced cool dialysate (35°C) for three sessions felt more energetic after those dialysis sessions and...
requested to be always dialysed with cool dialysate [73]. Assessment of patient expectations and patient education before the introduction of cool dialysate may be beneficial for increasing patient tolerance. Alternatively, individualizing cool dialysate temperature to individual pre-dialysis core body temperatures still maintained the beneficial effects on intradialysis BP and myocardial stunning, while causing no patient distress [74].

UFR
Recent studies have consistently shown the detrimental effects of higher UFR on the incidence of IDH and cardiovascular/all-cause mortality [19, 20, 75]. Thus, decreasing UFR is a promising intervention. The Dialysis Outcomes and Practice Patterns Study (DOPPS), which included 22 000 HD patients from seven countries, found that a UFR >10 mL/h/kg correlated with higher odds of IDH (odds ratio (OR) 1.30; P = 0.045) and a higher risk of all-cause mortality (relative risk 1.09; P = 0.02), while there was no association between UFR and cardiovascular mortality [18]. A smaller study of 287 HD patients also found that high UFR was independently associated with mortality (HR 1.22, P < 0.0001) and estimated a relative receiver operating characteristic curve cut-off value of 12.4 mL/h/kg UFR for predicting death within 5 years [19]. Flythe et al. [20] compared three categories of UFR for associated mortalities: UFR <10, 10–13 and >13 mL/h/kg. The risk of all-cause and cardiovascular mortalities began to increase at UFRs >10 mL/h/kg in spline analysis. Of note, all studies so far were observational. Thus they did not completely exclude the existence of potential confounders, such as RRF, that explain the association between UFR and mortality [75]. In this regard, the issue will only be settled by randomized controlled clinical trials that explore whether decreasing IDH by decreasing UFR has an impact on mortality.

Nevertheless, in 2015 the Kidney Care Quality Alliance set two fluid-related quality measures, including avoidance of high UFRs (>13 mL/h/kg), hoping to decrease the incidence of IDH, end organ damage in the heart, brain and kidney and mortality [19, 20, 75]. Decreasing the UFR may be achieved by having longer or more frequent dialysis sessions, which may deter many clinics and patients from such an intervention, or by limiting interdialysis weight gain discussed below) [75]. The introduction of biofeedback mechanisms may limit the impact on dialysis session duration or frequency by individualizing the UFR continuously in response to momentary BP and blood volume changes. Most biofeedback devices continuously monitor BP or estimate plasma refilling from the relative blood volume calculated from haematocrit changes. This information is then processed by the software to adjust the UFR and conductivity accordingly. In a meta-analysis including eight studies, biofeedback significantly decreased the incidence of IDH [risk ratio 0.61 (95% CI 0.44–0.86)] [76]. However, the evidence for an effect on mortality lacked sufficient power for evaluation [76]. Large randomized clinical trials are required to assess the impact of biofeedback devices on hard outcomes.

Accurate estimation of target dry weight is crucial for every HD patient. Although it is usually done clinically, novel methods assess target dry weight objectively, including bioelectrical impedance spectroscopy (BIS), lung ultrasonography (US) and measurement of the inferior vena cava [77–80]. BIS measures the fluid status through the body resistance to electrical currents. In a cross-sectional study including 194 HD patients, patients who had hypovolaemia by multifrequency bioimpedance developed more frequent IDH episodes [81]. BIS can be used to identify patients prone to IDH and prevent IDH development, as well as to routinely assess post-dialysis target dry weight. In a randomized controlled trial including 298 Asian HD patients, BIS-based post-dialysis target weight assessment significantly lowered the incidence of IDH when compared with clinical-based assessment (6.10 versus 6.62%, P < 0.05) and improved hypertension control, while the incidence rate for all-cause hospitalization and mortality did not significantly differ [82]. Another randomized control trial of 131 HD patients observed a greater decline in relative fluid overload and carotid and femoral pulse wave velocities, a marker of arterial stiffness, in the bioimpedance-assessed group than in the clinically assessed group after 2.5 years, which indicated improved cardiovascular end points, while the frequency of IDH between the groups did not differ [83]. In 2017, a meta-analysis on the effect of bioimpedance-estimated dry weight on mortality in HD patients revealed no association between the use of BIS and all-cause mortality [84].

Besides BIS, lung US is emerging as a reliable and non-invasive estimate of body fluid status. Lung US detects lung congestion using the B-line score, a straightforward yet training-requiring tool [85]. While the use of BIS and lung US are accepted as accurate tools to assess volume overload [85, 86], their long-term outcomes and associations with IDH are yet to be confirmed. In a randomized clinical trial including 250 HD patients, dry weight assessment based on lung US with bioimpedance was not superior to clinical assessment in terms of all-cause mortality, cardiovascular outcomes or IDH frequency [79].

Sodium profiling
The ideal sodium concentration of dialysate has long been a topic of discussion [87]. Waste removal by diffusion during HD decreases extracellular fluid osmolality and causes a shift of extracellular fluid into cells. Such a shift is avoided by raising dialysate sodium concentrations, which restores the osmotic gradient and plasma refill. Yet, increasing the sodium concentration causes thirst and volume expansion and increases BP [88]. Excess sodium has additional adverse consequences, independent of its osmotic effects, such as increasing endothelial cell stiffness [89], impairing nitric oxide release [89] and increasing sympathetic outflow [90]. Sodium profiling is proposed to limit such negative effects. During sodium profiling (modelling), dialysate sodium concentration is high in the beginning of the dialysis session and is gradually decreased as waste solutes are cleared from plasma. In a meta-analysis of 10 studies comparing two methods of sodium modelling, stepwise profiling significantly reduced IDH, while linear sodium profiling did not [91]. A more recent randomized, triple-blind, crossover clinical trial randomly assigned 80 patients to four different combinations of sodium modelling (decreasing from 150 to 138 mmol/L) and/or a dialysate sodium concentration is high in the beginning of the dialysis session and is gradually decreased as waste solutes are cleared from plasma. In a meta-analysis of 10 studies comparing two methods of sodium modelling, stepwise profiling significantly reduced IDH, while linear sodium profiling did not [91]. A more recent randomized, triple-blind, crossover clinical trial randomly assigned 80 patients to four different combinations of sodium modelling (decreasing from 150 to 138 mmol/L) and/or a dialysate temperature reduction (35°C) in changing orders. The two treatment schedules that included sodium profiling reduced the number of IDH episodes when compared with control or cool dialysate, while cool dialysate reduced IDH episodes compared with standard dialysis but had no additive effect on sodium profiling [92]. Yet, interdialysis weight gain was not reported, possibly obscuring the negative effects of sodium profiling. Thus, despite the positive impact of sodium profiling on IDH episodes, a recent analysis of the DOPPS cohort, which included 10 250 patients in 273 international facilities, showed that the routine use of sodium profiling to prevent IDH was actually associated with higher all-cause and cardiovascular mortality [HR 1.36 (95% CI 1.14–1.63) and HR 1.34 (95% CI 1.04–1.73),
respectively] [93]. Due to the conflicting evidence and concerns about safety, EBPGs currently do not recommend sodium profiling [10] (Table 2).

**High-flux haemofiltration**

High-flux convection was suggested to reduce IDH episodes when compared with diffusive techniques like low-flux HD [94]. In two consecutive studies by the Sardinian Collaborative Group, pre-dilution online haemofiltration was associated with fewer IDH episodes than high-flux HD (P < 0.04 and P = 0.003, respectively) [95, 96]. A more recent multi-centre, open-label randomized study assessed the number of IDH episodes in 146 long-term dialysis patients on low-flow HD, online pre-dilution haemofiltration and/or haemodiafiltration. The frequency of IDH episodes increased for HD (from 7.1 to 7.9%) and decreased for haemofiltration (from 9.8 to 8.0%) and, above all, for haemodiafiltration (from 10.6 to 5.2%) (P < 0.001) when compared with the run-in HD period. However, the pre-dialysis SBP significantly increased in the haemofiltration group, suggesting a positive sodium balance as an explanation for the decreased IDH episodes [94]. The impact of haemofiltration on mortality is still controversial, despite a clinical trial concluding that high-efficiency post-dilution online haemofiltration reduces all-cause mortality in HD patients [97–99].

**Midodrine**

Midodrine is an oral prodrug alpha 1 adrenergic receptor agonist that is removed via HD with a half-life of 3 h [100]. In a meta-analysis including 117 patients from 10 studies, midodrine was associated with a 13.3 mmHg (95% CI 8.6–18.0) higher nadir SBP, and 6/10 studies reported improved IDH symptoms. No adverse effects were reported, but the number of patients studied was too low [101]. In this regard, in a recent retrospective observational study of 1046 patients who were prescribed midodrine for IDH and 2037 controls it was found that midodrine use was associated with a higher adjusted incidence rate ratio of mortality [1.37 (95% CI 1.15–1.62)] and all-cause and cardiovascular hospitalization [1.31 (95% CI 1.19–1.43) and 1.41 (95% CI 1.17–1.71), respectively]. Although the models were adjusted for the presence of cardiovascular morbidities and residual confounding may affect the results [102], the safety signal identified suggests that midodrine should not be routinely used for IDH until prospective clinical trials confirm its safety and efficacy.

**L-carnitine**

L-carnitine transports cytosolic long-chain fatty acids as acylcarnitines across the inner mitochondrial membrane for β-oxidation and subsequent adenosine triphosphate production in the mitochondria and thus it is required for optimal energy production by, among others, cardiovascular cells. As with other molecules, it may be lost in the dialysate and it was suggested that L-carnitine supplementation may prevent IDH and European Best Practice guidelines (EBPGs) state that ‘carnitine supplementation should be considered for the prevention of IDH if other treatment options have failed’ [10]. However, a 2008 meta-analysis of five studies concluded that the available evidence does not confirm a beneficial effect of L-carnitine supplementation on IDH [103] and a more recent randomized clinical trial enrolling 92 patients that had IDH as a secondary endpoint did not find any differences between intravenous L-carnitine and placebo [104]. However, an even more recent, but small trial (n = 33, n = 7–10 per group) enriched in patients with a past history of IHD did observe significantly fewer IDH episodes in patients supplemented with intravenous L-carnitine prior to the HD session [105]. We should be aware that oral L-carnitine supplementation may result in the increased formation of the uraemic toxin trimethylamine N-oxide [106].

**Fluid administration**

Fluid administration, including colloids and crystalloids, has long been used to reverse IDH. Isotonic saline administration is problematic since it limits the achievement of a negative fluid balance. Hypertonic saline and colloids, including albumin, have also been used during the episode [107]. Mannitol is a well-known medication to boost intravascular volume [100], although its efficacy as a therapy and prophylactic agent for IDH is questionable [108]. In a prospective study including 102 patients, routine (preventive) mannitol administration before the dialysis session was associated with a 5.4 mmHg higher nadir SBP (P = 0.03), 25% less decline in SBP (P = 0.03) and 50% lower odds of having a hypotensive event (OR 0.50 (95% CI 0.29–0.83)) in adjusted models [109]. However, a double-blind randomized controlled trial by the same group enrolling 52 patients could not confirm the effect of mannitol administration on SBP decline during dialysis sessions and the decrease in IDH risk was of borderline significance (P = 0.05) [110]. Of note, neither study addressed the impact on volume overload or long-term effects.

**Food intake**

The overall impact of food consumption during the HD session on IDH is controversial. Given that malnutrition and hypoalbuminaemia are prevalent in ESRD patients undergoing dialysis, commonly referred to as protein-energy wasting, and are strong predictors of mortality, in-centre supplementation of high-protein meals during HD appears to be practical and cost effective [111]. Yet there are concerns about an increased incidence of IDH with such intervention. In an observational study including 166 HD patients, food and fluid consumption during dialysis sessions was a strong predictor for IDH (P = 0.003) and the need for mannitol use (P = 0.000). The consumption of >200 calories increased the risk of IDH 2-fold, but this was not statistically significant (P = 0.058) [112]. Similarly, a randomized crossover study of 13 patients reported an increased incidence of symptomatic IDH requiring intervention with food intake during dialysis (P = 0.025) [113]. These results can be explained with the hypothesis that increased splanchnic blood flow predisposes to IDH due to redistribution of blood volume, as discussed above. However, another observational study including 126 HD patients found no correlation between food intake and the number of IDH episodes [114]. Additionally, in a very recent non-randomized parallel-arm study including 18 HD patients, a high-protein meal during dialysis sessions did not change the frequency of symptomatic IDH. The different results may depend on the population studied (general dialysis populations versus IDH-prone individuals), the local HD session prescription practices and the nature of the food provided. Larger, long-term studies are warranted that explore the impact of high-protein supplementation during dialysis in individuals prone to IDH.

**Intradialytic exercise and intermittent pneumatic compression of the lower limbs**

Intradialytic exercise has been studied recently as a new promising therapy for IDH. In a randomized trial including 22 HD patients, a combination of aerobic exercise with bicycle
ergometer and anaerobic exercise with elastic bands decreased the incidence of IDH \( (P < 0.05) \) [115]. A randomized crossover study of 21 HD patients compared the effects of cyclic exercise and intermittent pneumonic compression of the lower limbs during the first hour of dialysis sessions with controls (no intervention). Only pneumonic compression significantly decreased IDH frequency (24\% versus 43\% of control patients, \( P = 0.014 \)), while the modest reduction with exercise (38\% of patients) was not statistically significant [116]. A recently completed (30 April 2019) randomized crossover clinical trial including 112 HD patients evaluated the impact of early versus late (during the HD session) intradialytic exercise on IDH, but results are not currently available (ClinicalTrials.gov identifier NCT03504943). Further investigations on the utility of pneumonic compression for IDH are warranted.

**Lower IDWG**

Since the rapid loss of volume by ultrafiltration is one of the main drivers of IDH, restricting the IDWG is one approach to prevent IDH. Preservation of RRF by avoiding the use of nephrotoxic agents and excessive ultrafiltration in incident dialysis patients is the key to maintain low IDWG for longer periods. Dietary sodium restriction is also a key factor limiting IDWG. This is a key concept that should be carefully explained to incident patients and new dialysis unit staff: there is a widespread misconception that the key to low IDWG is low fluid intake; however, thirst will make impossible any attempt at decreasing fluid intake when there is no concomitant dietary sodium restriction. Furthermore, education on occult sources of sodium is necessary, as well as dietary recommendations for alternative flavouring agents. Unfortunately, sodium restriction is not always possible to accomplish in daily practice. Low-salt processed foods are hard to find, patients may not be able to cook with raw ingredients and their long-established dietary preferences frequently prevent such personal sacrifice [117]. Nevertheless, strict salt restriction resulted in less frequent IDH episodes, lower left ventricular mass and less left ventricular hypertrophy compared with antihypertensive drug usage [118]. In patients with RRF, high-dose furosemide, as practiced in the USA, may increase urine output and decrease IDWG [119].

**BP-lowering drugs**

As many as 50–90\% of ESRD patients suffer from hypertension [120] and finding the balance between antihypertensive management and IDH risk can be a huge challenge. The mainstream practice is withholding BP-lowering medications prior to HD sessions [120]. In a UK-based cohort study of 2630 HD patients, the number of IDH episodes was significantly higher in patients who were not on antihypertensive drugs than in patients on antihypertensive drugs [121]. The pre-dialysis BP values in the two groups were not significantly different, but it is not possible to eliminate the bias arising from the different haemodynamic characteristics of the patients who do and do not need antihypertensive medications to achieve the same BP target. A small double-blind crossover study with 10 patients assessed the effect of verapamil, a non-dihydropyridine calcium channel blocker, administered 1 h before dialysis on the occurrence of IDH. Verapamil was chosen because of its benefits on left ventricular compliance and relaxation, with less pronounced vasodilatory effects. Two 2-week verapamil periods alternated with two 2-week placebo periods. No significant difference was found in the severity or frequency of IDH episodes between the periods [122]. Another study monitored the initiation of atenolol in eight hypertensive HD patients. The drug was given thrice weekly at the end of each HD session and the study found MAP was successfully reduced with no effect on IDH [123]. However, the drug was administered at the end of HD sessions and not in between, thus not directly exploring the impact of same-day, prior-to-HD-session antihypertensive drugs and IDH. In a study with 21 hypertensive HD patients, the incidence of IDH episodes did not increase after the addition of antihypertensive medications [124]. A similar result was found in a randomized, placebo-controlled trial including 251 hypertensive HD patients, where the administration of amlodipine 10 mg did not cause a significant difference in the frequency of IDH episodes while successfully decreasing mean pre-dialysis BP [125]. Of note, these studies only included hypertensive patients who needed BP-lowering medications, presumably hypotension-resistant patients. Current evidence is not enough to assess the benefits and disadvantages of withholding antihypertensives and to compare IDH risks of different antihypertensive medications.

**Switching to PD**

The ultimate solution to intractable IDH is changing the dialysis modality to PD, since IDH is mainly a complication of HD and is not seen in PD. A careful assessment of the potential barriers for PD and the patient’s desire to perform self-care is needed.

**LIMITATIONS AND A ROADMAP FOR IDH RESEARCH**

Currently the most important limitation of IDH research is the lack of a consensus IDH definition. Current definitions based on symptoms and/or interventions are clinically relevant but not well suited for large-scale studies. This is also the case for definitions in other fields of nephrology. For example, the AKI definition based on urinary output is not well suited for large-scale studies. Thus we propose to develop a novel consensus definition using large-scale data focused on both short-term (hospitalization) and long-term (mortality) outcomes. That is, as for other definitions, ranging from hypertension and hypercholesterolaemia to chronic kidney disease or AKI, the consensus definition should be based on the implications for health, i.e. on the risk for adverse outcomes, of specific BP thresholds. The definition may have two aspects: a threshold BP to define an individual IDH episode and a frequency parameter identifying what number of IDH episodes per unit of time is clinically relevant. Ideally, the threshold BP to define an individual IDH episode should be based on big data analysis and may be represented by an absolute drop in systolic or mean BP, by a percentage drop in systolic or mean BP over baseline, by an absolute SBP nadir or by a BP nadir that represents a percentage of baseline values, among others. Thus we should be open to novel concepts regarding the definition of a BP threshold. A consensus IDH definition usable in large databases may facilitate the development of larger, long-term prospective observational studies or clinical trials that would provide evidence-based indicators of IDH and guidelines for the prevention and treatment of IDH [14] (Figure 2).

**ACKNOWLEDGEMENTS**

M.K. gratefully acknowledges the use of the services and facilities of the Koc University Research Center for
Translational Medicine (KUTTAM), funded by the Presidency of Turkey, Presidency of Strategy and Budget. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Presidency of Strategy and Budget.

**FUNDING**

Research by the authors was supported by a grant from Ministry of Research and Innovation, CNCS-UEFISCDI, project number PN-III-P4-ID-PCE-2016-0908, contract number 167/2017, within PNCDI III, ISCIII FIS P116/02057, PI19/00588, P119/00815, DTS18/00032, ERA-PerMed-JTC2018, AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009 FEDER funds, Fundación Renal Inigo Alvarez de Toledo (FRIAT), Comunidad de Madrid CIFRA2 B2017/BMD-3686.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**REFERENCES**

1. Saran R, Robinson B, Abbott KC et al. US Renal Data System 2018 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2019; 73: A7–A8

2. Yu J, Liu Z, Shen B et al. Intradialytic hypotension as an independent risk factor for long-term mortality in maintaining hemodialysis patients: a 5-year follow-up cohort study. *Blood Purif* 2018; 45: 320–326

3. Okoye OC, Slater HE, Rajora N. Prevalence and risk factors of intra-dialytic hypotension: a 5 year retrospective report from a single Nigerian Centre. *Pan Afr Med J* 2017; 28: 62

4. Rocha A, Sousa C, Teles P et al. Effect of dialysis day on intradialytic hypotension risk. *Kidney Blood Press Res* 2016; 41: 168–174

5. Kuipers J, Verboom LM, Ipema KJR et al. The prevalence of intradialytic hypotension in patients on conventional hemodialysis: a systematic review with meta-analysis. *Am J Nephrol* 2019; 49: 497–506

6. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis* 2005; 45(4 Suppl 3): S1–S153
7. Stefansson BV, Brunelli SM, Cabrera C et al. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol 2014; 9: 2124–2132
8. Mactier R, Hoenich N, Breen C. Renal Association clinical practice guideline on haemodialysis. Nephron Clin Pract 2011; 118: C241–C286
9. Davenport A, Cox C, Thurasingham R. Blood pressure control and symptomatic intradialytic hypotension in diabetic haemodialysis patients: a cross-sectional survey. Nephron Clin Pract 2008; 109: c65–c71
10. Kooiman J, Basci A, Pizzarelli F et al. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant 2007; 22: ii22–ii44
11. Hirakata H, Nitta K, Inaba M et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial 2012; 16: 387–435
12. Chou JA, Streja E, Nguyen DV et al. Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant 2018; 33: 149–159
13. Sands JI, Usvyat LA, Sullivan T et al. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int 2014; 18: 415–422
14. Assimon MM, Flythe JE. Definitions of intradialytic hypotension. Semin Dial 2017; 30: 464–472
15. Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E et al. Clarifying the concept of chronic kidney disease for non-nephrologists. Clin Kidney J 2019; 12: 258–261
16. Flythe JE, Xue H, Lynch KE et al. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol 2015; 26: 724–734
17. Singh AT, Mc Causland FR. Osmolality and blood pressure stability during hemodialysis. Semin Dial 2017; 30: 509–517
18. Saran R, Bragg-Gresham JL, Levin NW et al. Association between high ultrafiltration rates and mortality in uremic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007; 22: 3547–3552
19. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2011; 79: 250–257
20. Daugirdas JT. Pathophysiology of dialysis hypotension: an update. Am J Kidney Dis 2001; 38(4 Suppl 4): S11–S17
21. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884–890
22. Owen PJ, Priestman WS, Sigrist MK et al. Myocardial contractile function and intradialytic hypotension. Hemodial Int 2009; 13: 293–300
23. Nette RW, van den Dorpel MA, Krepel HP et al. Hypotension during hemodialysis results from an impairment of arterial tone and left ventricular function. Clin Nephrol 2005; 63: 276–283
24. Daul AE, Wang XL, Michel MC et al. Arterial hypotension in chronic hemodialyzed patients. Kidney Int 1987; 32: 728–735
25. Kanbay M, Afsar B, Gusbeth-Tatomir P et al. Arterial stiffness in dialysis patients: where are we now? Int Urol Nephrol 2010; 42: 741–752
26. Shaft T, Mullangi S, Jaar BG et al. Autonomic dysfunction as a mechanism of intradialytic blood pressure instability. Semin Dial 2017; 30: 537–544
27. Gul A, Miskulin D, Harford A et al. Intradialytic hypotension. Curr Opin Nephrol Hypertens 2016; 25: 545–550
28. Barnas MG, Boer WH, Koornans HA. Hemodynamic patterns and spectral analysis of heart rate variability during dialysis hypotension. J Am Soc Nephrol 1999; 10: 2577–2584
29. Park S, Kim WJ, Cho NJ et al. Predicting intradialytic hypotension using heart rate variability. Sci Rep 2019; 9: 2574
30. Chan CT, Chertow GM, Daugirdas JT et al. Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) daily trial. Nephrol Dial Transplant 2014; 29: 168–178
31. Kanbay M, Yilmaz S, Dincer N et al. Antidiuretic hormone and serum osmolality physiology and related outcomes: what is old, what is new, and what is unknown? J Clin Endocrinol Metab 2019; 104: 5406–5420
32. Ottema EM, Zittema D, Kuipers J et al. Dialysis hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and meta-analysis. Am J Nephrol 2014; 39: 100–109
33. Cernaro V, Lacquaniti A, Lorenzano G et al. Apelin, plasmatic osmolality and hypotension in dialyzed patients. Blood Purif 2012; 33: 317–323
34. van der Zee S, Thompson A, Zimmerman R et al. Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int 2007; 71: 318–324
35. Lindberg JS, Copley JB, Melton K et al. Lysine vasopressin in the treatment of refractory hemodialysis-induced hypotension. Am J Nephrol 1990; 10: 269–275
36. Shimizu K, Kurowsawa T, Sanjo T. Effect of hyperosmolality on vasopressin secretion in intradialytic hypotension: a mechanistic study. Am J Kidney Dis 2008; 52: 294–304
37. Daugirdas JT. Intradialytic hypotension and splanchnic shifting: Integrating an overlooked mechanism with the detection of ischemia-related signals during hemodialysis. Semin Dial 2019; 32: 243–247
38. Barakat MM, Nawab ZM, Yu AW et al. Hemodynamic effects of intradialytic food ingestion and the effects of caffeine. J Am Soc Nephrol 1993; 3: 1813–1818
39. Cho A, Lee YK, Oh J et al. The relationship between intradialytic hypotension and vascular calcification in hemodialysis patients. PLoS One 2017; 12: e0185846
40. Lai CT, Wu CJ, Chen HH et al. Absolute interdialytic weight gain is more important than percent weight gain for intradialytic hypotension in heavy patients. Nephrology (Carlton) 2012; 17: 230–236
41. Shoji T, Tsubakihara Y, Fuji M et al. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212–1220
42. Tisler A, Akocsi K, Borbas B et al. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant 2003; 18: 2601–2605
43. Tisel JB, Stiefers HJ, Selby NM et al. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4: 914–920
44. Canty JM, Jr, Fallavollita JA. Chronic hibernation and chronic stunning: a continuum. J Nucl Cardiol 2000; 7: 509–527
45. Selby NM, Burton JO, Chesterton LJ et al. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol 2006; 1: 1216–1225
Intradialytic hypotension

47. Selby NM, Lambie SH, Camici PG et al. Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis 2006; 47: 830–841
48. Brunelli SM, Sibbel S, Do TP et al. Facility dialysate calcium practices and clinical outcomes among patients receiving hemodialysis: a retrospective observational study. Am J Kidney Dis 2015; 66: 655–665
49. Henrich WL, Hunt JM, Nixon JV. Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 1984; 310: 19–23
50. van der Sande FM, Cherix EC, van Kuijk WH et al. Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients. Am J Kidney Dis 1998; 32: 125–131
51. MacEwen C, Sutherland S, Daly J et al. Relationship between hypotension and cerebral ischemia during hemodialysis. J Am Soc Nephrol 2017; 28: 2511–2520
52. Mizumasa T, Hirakata H, Yoshimitsu T et al. Dialysis-related hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients: a 3-year prospective study. Nephron Clin Pract 2004; 97: c23–c30
53. Eldehni MT, Oduodu A, McIntyre CW. Randomized clinical trial of dialysate cooling and effects on brain white matter. J Am Soc Nephrol 2015; 26: 957–965
54. Assimon MM, Wang L, Flythe JE. Cumulative exposure to frequent intradialytic hypotension associates with new-onset dementia among elderly hemodialysis patients. Kidney Int Rep 2019; 4: 603–606
55. Wolfgam DF. Intradialytic cerebral hyperperfusion as mechanism for cognitive impairment in patients on hemodialysis. J Am Soc Nephrol 2019; 30: 2052–2058
56. Ortiz A, Garron MP, Navarro A et al. Ischaemic hepatic necrosis and intestinal infarction in a haemodialysis patient. Nephrol Dial Transplant 1991; 6: S21–S23
57. Seong EY, Zheng Y, Winkelmayer WC. The relationship between intradialytic hypotension and hospitalized mesenteric ischemia: a case-control study. Clin J Am Soc Nephrol 2018; 13: 1517–1525
58. Ori Y, Chagnac A, Schwartz A et al. Non-occlusive mesenteric ischemia in chronically dialyzed patients: a disease with multiple risk factors. Nephron Clin Pract 2005; 101: c87–93
59. John AS, Tuerff SD, Kerstein MD. Nonocclusive mesenteric infarction in hemodialysis patients. J Am Coll Surg 2000; 190: 84–88
60. Shemesh A, Margolin E. Sequential nonarteritic anterior ischemic optic neuropathy in patient on chronic hemodialysis. CEN Case Rep 2019; 8: 89–94
61. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69: 1726–1732
62. Shenmin D, Bostom AG, Laliberty P et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 85–90
63. Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046–1053
64. Iest CG, Vanholder RC, Ringoir SM. Loss of residual renal function in patients on regular haemodialysis. Int J Artif Org 1989; 12: 159–164
65. Chang TI, Paik J, Greene T et al. Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol 2011; 22: 1526–1533
66. Caplin B, Kumar S, Davenport A. Patients’ perspective of haemodialysis-associated symptoms. Nephrol Dial Transplant 2011; 26: 2656–2663
67. Kuipers J, Oosterhuis JK, Faans W et al. Association between quality of life and various aspects of intradialytic hypotension including patient-reported intradialytic symptom score. BMC Nephrol 2019; 20: 164
68. Toth-Manikowski SM, Sozio SM. Cooling dialysate during in-center hemodialysis: beneficial and deleterious effects. World J Nephrol 2016; 5: 166–171
69. Mustafa RA, Baidar F, Akl EA et al. Effect of lowering the dialysate temperature in chronic hemodialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2016; 11: 442–457
70. Selby NM, McIntyre CW. A systematic review of the clinical effects of reducing dialysate fluid temperature. Nephrol Dial Transplant 2006; 21: 1883–1898
71. Oduodu A, Eldehni MT, McCann GP et al. Randomized controlled trial of individualized dialysate cooling for cardiac protection in hemodialysis patients. Clin J Am Soc Nephrol 2015; 10: 1408–1417
72. Lima EQ, Silva RG, Donadi EL et al. Prevention of intradialytic hypotension in patients with acute kidney injury submitted to sustained low-efficiency dialysis. Ren Fail 2012; 34: 1238–1243
73. Ayoub A, Finlayson M. Effect of cool temperature dialysate on the quality and patients’ perception of haemodialysis. Nephrol Dial Transplant 2004; 19: 190–194
74. Jefferies HJ, Burton JO, McIntyre CW. Individualised dialysate temperature improves intradialytic haemodynamics and abrogates haemodialysis-induced myocardial stunning, without compromising tolerability. Blood Purif 2011; 32: 63–68
75. Flythe JE. Ultrafiltration rate clinical performance measures: ready for primetime? Semin Dial 2016; 29: 425–434
76. Nesrallah GE, Suri RS, Guyatt G et al. Biofeedback dialysis for hypotension and hypervolemia: a systematic review and meta-analysis. Nephrol Dial Transplant 2013; 28: 182–191
77. Gullapudi VRL, Kazmi I, Selby NM. Techniques to improve intradialytic haemodynamic stability.Curr Opin Nephrol Hypertens 2018; 27: 413–419
78. Ekinci C, Karabork M, Siroipol D et al. Effects of volume overload and current techniques for the assessment of fluid status in patients with renal disease. Blood Purif 2018; 46: 34–47
79. Siroipol D, Onofriescu M, Voroneanu L et al. Dry weight assessment by combined ultrasound and bioimpedance monitoring in low cardiovascular risk hemodialysis patients: a randomized controlled trial. Int Urol Nephrol 2017; 49: 143–153
80. Siroipol D, Voroneanu L, Hogas S et al. Bioimpedance analysis versus lung ultrasonography for optimal risk prediction in hemodialysis patients. Int J Cardiovasc Imaging 2016; 32: 263–270
81. Kalainy S, Reid R, Jindal K et al. Fluid volume expansion and depletion in hemodialysis patients lack association with clinical parameters. Can J Kidney Health Dis 2015; 2: 90
82. Huan-Sheng C, Yeong-Chang C, Ming-Hsing H et al. Application of bioimpedance spectroscopy in Asian dialysis patients (ABISAD-III): a randomized controlled trial for clinical outcomes. Int Urol Nephrol 2016; 48: 1897–1909
83. Onofriescu M, Hogas S, Voroneanu L et al. Bioimpedance-guided fluid management in maintenance hemodialysis: a...
pilot randomized controlled trial. *Am J Kidney Dis* 2014; 64: 111–118
84. Covic A, Ciumanghel AI, Siriopol D et al. Value of bioimpedance analysis estimated “dry weight” in maintenance dialysis patients: a systematic review and meta-analysis. *Int Urol Nephrol* 2017; 49: 2231–2245
85. Ross DW, Abbasi MM, Jhaveri KD et al. Lung ultrasonography in end-stage renal disease: moving from evidence to practice—a narrative review. *Clin Kidney J* 2018; 11: 172–178
86. Park JH, Jo YI, Lee JH. Clinical usefulness of bioimpedance analysis for assessing volume status in patients receiving maintenance dialysis. *Korean J Intern Med* 2018; 33: 660–669
87. Perez-Gomez MV, Gonzalez-Parra E, Ortiz A. Haemodialysis: long neglected, difficult to optimize, may modify hard outcomes. *Clin Kidney J* 2015; 8: 576–579
88. Kanbay M, Afsar B et al. Acute effects of salt on blood pressure are mediated by serum osmolality. *J Clin Hypertens* 2018; 20: 1447–1454
89. Ebrahimi H, Safavi M, Saeidi MH et al. Value of bioimpedance analysis estimated “dry weight” in maintenance dialysis patients: a systematic review and meta-analysis. *Int Urol Nephrol* 2017; 49: 2231–2245
90. Dunne N. A meta-analysis of sodium profiling techniques. *Clin Kidney J* 2018; 11: 172–178
91. Ross DW, Abbasi MM, Jhaveri KD et al. Lung ultrasonography in end-stage renal disease: moving from evidence to practice—a narrative review. *Clin Kidney J* 2018; 11: 172–178
92. Park JH, Jo YI, Lee JH. Clinical usefulness of bioimpedance analysis for assessing volume status in patients receiving maintenance dialysis. *Korean J Intern Med* 2018; 33: 660–669
93. Perez-Gomez MV, Gonzalez-Parra E, Ortiz A. Haemodialysis: long neglected, difficult to optimize, may modify hard outcomes. *Clin Kidney J* 2015; 8: 576–579
94. Covic A, Ciumanghel AI, Siriopol D et al. Value of bioimpedance analysis estimated “dry weight” in maintenance dialysis patients: a systematic review and meta-analysis. *Int Urol Nephrol* 2017; 49: 2231–2245
95. Altieri P, Sorba GB, Bolasco PG et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. *J Am Soc Nephrol* 2010; 21: 1798–1807
96. Altieri P, Sorba GB, Bolasco PG et al. On-line predilution hemofiltration versus ultrapure high-flux hemodialysis: a multicenter prospective study in 23 patients. Sardinian Collaborative Study Group of On-Line Hemofiltration. *Blood Purif* 1997; 15: 169–181
97. Maduell F, Moreto F, Pons M et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *J Am Soc Nephrol* 2013; 24: 487–497
98. Mostovaya IM, Grooteman MP, Basile C et al. High convection volume in online post-dilution haemodiafiltration: relevance, safety and costs. *Clin Kidney J* 2015; 8: 368–373
99. Chapdelaine I, de Roij van Zuijdwijn CL, Mostovaya IM et al. Optimization of the convection volume in online post-dilution haemodiafiltration: practical and technical issues. *Clin Kidney J* 2015; 8: 191–198
100. Reilly RF. Attending rounds: a patient with intradialytic hypotension. *Clin J Am Soc Nephrol* 2014; 9: 798–803
101. Prakash S, Garg AX, Heidenheim AP, House AA. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. *Nephrol Dial Transplant* 2004; 19: 2553–2558
102. Brunelli SM, Cohen DE, Marlowe G et al. The impact of midodrine on outcomes in patients with intradialytic hypotension. *Am J Nephrol* 2018; 48: 381–388
103. Lynch KE, Feldman HI, Berlin JA et al. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis. *Am J Kidney Dis* 2008; 52: 962–971
104. Mercalde L, Coudert M, Vassault A et al. L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. *Clin J Am Soc Nephrol* 2012; 7: 1836–1842
105. Ibarra-Sifuentes HR, Del Cueto-Aguilera A, Gallegos-Aguirujo DA et al. Levocarnitine decreases intradialytic hypotension episodes: a randomized controlled trial. *Ther Apher Dial* 2017; 21: 459–464
106. Sanchez-Nino MD, Ortiz A. Differential effects of oral and intravenous L-carnitine on serum lipids: is the microbiota the answer? *Clin Kidney J* 2014; 7: 437–441
107. Van der Sande FM, Luik AJ, Kooman JP et al. Effect of intravenous fluids on blood pressure course during hemodialysis in hypertensive-prone patients. *J Am Soc Nephrol* 2000; 11: 550–555
108. Nguyen T, Veltchev K, Nguyen TV. Mannitol role in the management of intradialytic hypotension. *Am J Ther* 2018
109. McCausland FR, Prior LM, Heher E et al. Preservation of blood pressure stability with hypertonic mannitol during hemodialysis initiation. *Am J Nephrol* 2012; 36: 168–174
110. McCausland FR, Claggett B, Sabbisetti VS et al. Hypertonic mannitol for the prevention of intradialytic hypotension: a randomized controlled trial. *Am J Kidney Dis* 2019; 74: 483–490
111. Kalantar-Zadeh K, Ikizler TA. Let them eat during dialysis: an overlooked opportunity to improve outcomes in maintenance hemodialysis patients. *J Renal Nutr* 2013; 23: 157–163
112. Strong J, Burgett M, Buss ML et al. Effects of calorie and fluid intake on adverse events during hemodialysis. *J Renal Nutr* 2001; 11: 97–100
113. Zoccali C, Mallamaci F, Ciccarelli M et al. Postprandial alterations in arterial pressure control during hemodialysis in uremic patients. *Clin Nephrol* 1989; 31: 323–326
114. Benaroia M, Iliescu EA. Oral intake during hemodialysis: is there an association with intradialytic hypotension? *Hemodial Int* 2008; 12: 62–65
115. Rhee SY, Song JK, Hong SC et al. Intradialytic exercise improves physical function and reduces intradialytic hypotension and depression in hemodialysis patients. *Korean J Intern Med* 2019; 34: 588–598
116. Alvesas VRC, Ramos CD, Pereira BJ et al. Pneumatic compression, but not exercise, can avoid intradialytic hypotension: a randomized trial. *Am J Nephrol* 2017; 45: 409–416
117. Ok E. How to successfully achieve salt restriction in dialysis patients? What are the outcomes? *Blood Purif* 2018
118. Kayikcioğlu M, Tumuklu M, Ozkayha M et al. The benefit of salt restriction in the treatment of end-stage renal disease by hemodialysis. *Nephrol Dial Transplant* 2008; 24: 956–962
119. Hayani K, Kunzmann K, Mettang T et al. Lower prevalence of chronic itch in hemodialysis patients on loop diuretics: results from GEHIS (German Epidemiological Hemodialysis Itch Study). *J Eur Acad Dermatol Venereol* 2017; 31: 1333–1337
120. Wang KM, Sirich TL, Chang TI. Timing of blood pressure medications and intradialytic hypotension. Semin Dial 2019; 32: 201–204

121. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008; 73: 759–764

122. Sherman RA, Casale P, Cody R et al. Effect of predialysis verapamil on intradialytic blood pressure in chronic hemodialysis patients. ASAIO Trans 1990; 36: 67–69

123. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999; 55: 1528–1535

124. Takeda A, Toda T, Fujii T et al. Can predialysis hypertension prevent intradialytic hypotension in hemodialysis patients? Nephron Clin Pract 2006; 103: c137–c143

125. Tepel M, Hopfenmueller W, Scholze A et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 2008; 23: 3605–3612